Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis
Diagnostics · 03.11.2023 · 13 (21) · 3379
DOI: 10.3390/diagnostics13213379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 03.11.2023. Verfasst von Sabrina M Stollberg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Helsana Insurance Group, 8081 Zurich, Switzerland. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumor markers (TM) are crucial in the monitoring of cancer treatment. However, inappropriate requests for screening reasons have a high risk of false positive and negative findings, which can lead to patient anxiety and unnecessary follow-up examinations. We aimed to assess the appropriateness of TM testing in outpatient practice in Switzerland. We conducted a retrospective cohort study based on healthcare claims data. Patients who had received at least one out of seven TM tests (CEA, CA19-9, CA125, CA15-3, CA72-4, Calcitonin, or NSE) between 2018 and 2021 were analyzed. Appropriate determinations were defined as a request with a corresponding cancer-related diagnosis or intervention. Appropriateness of TM determination by patient characteristics and prescriber specialty was estimated by using multivariate analyses. A total of 51,395 TM determinations in 36,537 patients were included. An amount of 41.6% of all TM were determined appropriately. General practitioners most often determined TM (44.3%) and had the lowest number of appropriate requests (27.8%). A strong predictor for appropriate determinations were requests by medical oncologists. A remarkable proportion of TM testing was performed inappropriately, particularly in the primary care setting. Our results suggest that a considerable proportion of the population is at risk for various harms associated with misinterpretations of TM test results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences, Helsana Insurance Group, 8081 Zurich, Switzerland.
- Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
- Institute of Primary Care, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
ORCID-Profile: Michael Nagler
Zitieren
APA
Stollberg, S. M., Näpflin, M., Nagler, M., & Huber, C. A. (2023). Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis. Diagnostics, 13(21), 3379. https://doi.org/10.3390/diagnostics13213379
Vancouver
Stollberg SM, Näpflin M, Nagler M, Huber CA. Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis. Diagnostics. 2023;13(21):3379. doi:10.3390/diagnostics13213379
BibTeX
@article{Stollberg2023,
author = {Stollberg, Sabrina M and Näpflin, Markus and Nagler, Michael and Huber, Carola A},
title = {Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {21},
pages = {3379},
doi = {10.3390/diagnostics13213379}
}
EUVIMED